Nate Stebbins, PhD

Nate is Chief Strategy and Operations Officer of Expeditions Medicines.

Nate joined Expedition Medicines in 2022, crafting the company’s platform and product strategy and guiding it through multiple successful rounds of financing and partnerships. Prior to founding Expedition Medicines, he has founded or built multiple companies at the intersection of chemical biology, bioengineering, and AI, including Radial Therapeutics, where he served as Chief Scientific Officer, Kaleido Biosciences, and Cobalt, which was merged into Sana Biotechnology (NASDAQ: SANA). Alongside his roles in new companies, Nate is a Senior Principal at Flagship Pioneering, where he works with a team of entrepreneurial scientists to conceive, create, resource and grow first-in-class, first-in-category scientific ventures. 

Nate’s scientific work underpins 15+ patents and publications in journals like Cell. He holds a Ph.D. in biological engineering from MIT, where his research in Professor Ram Sasisekharan’s lab explored the role of cell surface sugars in disease, and a B.S. in biochemistry, cellular, and molecular biology from the University of Tennessee, where he was awarded the prestigious Goldwater Scholarship.